Stock Screener App

Frei -

Installieren

174.93

1.66% -2.96

after-market

Handel nachbörslich: 174.60 -0.33 -0.19%

Astrazeneca Plc (AZN)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt AZN? Forum Prognose Aktiensplit Dividendenhistorie

Astrazeneca Plc Aktie (AZN) Neueste Nachrichten

AstraZeneca (LSE:AZN) Stock Fair Value Edges Lower After Pipeline And Pricing Debate - Yahoo Finance

AstraZeneca (LSE:AZN) Stock Could Be 20.2% Undervalued After Recent Pullback - Yahoo Finance

Astrazeneca (AZN) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance

AstraZeneca slides Thursday, underperforms market - MarketWatch

AstraZeneca rallies Wednesday, outperforms market - MarketWatch

The Zacks Analyst Blog Highlights Applied Materials, GE, AstraZeneca, Team and Applied Energetics - Zacks Investment Research

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.

Top Stock Reports for Applied Materials, GE & AstraZeneca - Yahoo Finance

AstraZeneca (AZN) officer receives Ordinary Share award under incentive plan - Stock Titan

FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris - Yahoo Finance Singapore

AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold? - TradingView

ASTRAZENECA : Gets a Buy rating from Jefferies - marketscreener.com

AstraZeneca says AI is raising its odds where most drugs fail - thestreet.com

EHA26: AstraZeneca battles Roche in untreated follicular lymphoma - Yahoo Finance

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod - Benzinga

AstraZeneca slips Monday, underperforms market - MarketWatch

AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication - Yahoo Finance

FDA approves AstraZeneca’s Truqap for PTEN-deficient prostate cancer in US - Investing.com

US approves AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient metastatic prostate cancer - Stock Titan

DEFINED WEALTH MANAGEMENT, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 25.59% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews

FDA Grants Priority Review to AstraZeneca’s Ultomiris for Rare Kidney Disease Treatment (AZN) - Yahoo Finance UK

Astrazeneca secures US approval for Truqap combo in PTEN‑deficient prostate cancer - Sharecast.com

AstraZeneca's Ultomiris wins US FDA priority review in kidney disease - marketscreener.com

Astrazeneca Plc Gains US Approval For Truqap In PTEN-deficient Prostate Cancer - DirectorsTalk Interviews

TRUQAP Approval Adds Precision Prostate Cancer Upside To AstraZeneca Valuation - Yahoo Finance

AstraZeneca Receives Priority Review in the US for ULTOMIRIS as Treatment for Adults With Immunoglobulin A Nephropathy - marketscreener.com

AZN Stock Quote Price and Forecast - CNN

AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica

CVT Nasdaq-100 Index Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus

AVIP Nasdaq-100 Index Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus

AstraZeneca says Truqap combination approved in US for prostate cancer - London South East

AstraZeneca (AZN) Gains from New Diagnostic Test Approval - GuruFocus

AstraZeneca (AZN) Secures U.S. Approval for Innovative Prostate Cancer Treatment - GuruFocus

AstraZeneca Truqap Ok'd in U.S. for prostate cancer (AZN:NYSE) - Seeking Alpha

AstraZeneca : Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer - marketscreener.com

AstraZeneca PLC Stock (US6549022043): ADR inches higher on Nasdaq as pharma heavyweight stays in foc - AD HOC NEWS

AstraZeneca PLC Stock (US6549022043): Deutsche Bank sticks to Sell rating as shares edge higher - AD HOC NEWS

AstraZeneca PLC (AZN) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know - Yahoo Finance

Jazz, AstraZeneca, Astellas: Foreign healthcare's strongest quant picks - MSN

AstraZeneca PLC Stock (US6549022043): Obesity Drug Elecoglipron Heads Into Phase 3 As Shares Climb - AD HOC NEWS

ASTRAZENECA : Deutsche Bank maintains a Sell rating - marketscreener.com

ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations - Citeline News & Insights

Jim Cramer on AstraZeneca: “On Track to Hit the Ambitious Long-Term Financial Targets” - Yahoo Finance

Hansa Biopharma appoints Head of Business Development from AstraZeneca - marketscreener.com

AstraZeneca advances oral GLP-1 elecoglipron into phase 3 - MSN

AstraZeneca PLC stock (US6549022043): obesity drug data and pipeline momentum keep investors alert - AD HOC NEWS

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - Benzinga

Functional genomics and AI drive novel target discovery at AstraZeneca - Select Science

State Street Premier Growth Equity V.I.S. Fund's AstraZeneca PLC(AZN) Holding History - GuruFocus

ASTRAZENECA : JP Morgan remains its Buy rating - marketscreener.com

ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA - Clinical Trials Arena

AstraZeneca reprimanded over LinkedIn likes once again - Fierce Pharma

AstraZeneca Advances Obesity, Diabetes Medication Elecoglipron to Phase 3 Trial - marketscreener.com

AstraZeneca PLC (AZN) Stock Analysis: Robust Revenue Growth and a 20.73% Upside Potential - DirectorsTalk Interviews

ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com

NYLIM VP Income Builder Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus

BofA reiterates Buy on AstraZeneca stock, cites adjuvant trial outlook By Investing.com - Investing.com South Africa

AstraZeneca progresses elecoglipron after positive phase IIb results - London South East

Why is CAMBRIA-1 emerging as AstraZeneca’s key breast cancer catalyst? - Investing.com Nigeria

ASTRAZENECA : Jefferies remains its Buy rating - marketscreener.com

AstraZeneca Gears Up for Phase 3 Trial of Weight-loss Drug - marketscreener.com

IAMS WEALTH MANAGEMENT, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus

AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results - GuruFocus

Elecoglipron cut nearly 12% of body weight in study, AstraZeneca says - AOL.com

AstraZeneca unveils data behind Phase III-bound oral GLP-1 - FirstWord Pharma

AstraZeneca’s oral GLP-1 advances to Phase III after strong trial results - Investing.com Nigeria

NVS

$147.08

2.52%

MRK

$113.87

1.36%

NVO

$43.19

0.76%

AMGN

$337.60

1.19%

ABBV

$216.49

2.14%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters